发明名称 Clostridium Difficile Compositions and Methods of Use
摘要 Fusion proteins include full-length flagellin or portions of flagellin fused to at least one Clostridium difficile antigen. Fusion proteins can include a first Clostridium difficile antigen that replaces at least a portion or the entirety of domain 3 of flagellin and a second Clostridium difficile antigen fused to the carboxy terminal amino acid of flagellin. Fusion proteins can also include at least one Clostridium difficile antigen fused to the most carboxy terminus of portions of flagellin or full length flagellin. Methods that employ fusion proteins are administered to humans to ameliorate Clostridium difficile associated disease.
申请公布号 US2016166671(A1) 申请公布日期 2016.06.16
申请号 US201514875789 申请日期 2015.10.06
申请人 VaxInnate Corporation 发明人 Tussey Lynda;Song Langzhou;Umlauf Scott
分类号 A61K39/08;C07K16/12;A61K38/16 主分类号 A61K39/08
代理机构 代理人
主权项 1. A composition comprising: a) a first fusion protein that activates Toll-like Receptor 5 and includes flagellin fused to at least one Clostridium difficile toxin A antigen; b) a second fusion protein that activates Toll-like Receptor 5 and includes flagellin fused to at least one Clostridium difficile toxin B antigen, and c) a third fusion protein that activates Toll-like Receptor 5 and includes flagellin fused to at least one Clostridium difficile binary toxin antigen.
地址 Cranbury NJ US